Follow The Filings

ANTX AN2 Therapeutics

AN2 Therapeutics earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 11 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by ANTX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ANTX insider trades
  • $12K bought by 1 insider
  • None no sales outside a trading plan
  • $317K sold by 1 insider under 10b5-1 plans
  1. Robin Shane Readnour Director
    Planned sale
    $6,675 1,108 shares at $6.02 0.2% of stake
    Traded Sep 9 Filed Sep 11
    ↗
  2. Robin Shane Readnour Director
    Planned sale
    $97K 16,119 shares at $6.04 2.5% of stake
    Traded Sep 3–8 Filed Sep 8
    ↗
  3. Margaret M FitzPatrick Director
    Buy
    $12K 2,098 shares at $5.53 +24% to stake
    Traded Sep 1 Filed Sep 2
    ↗
  4. Robin Shane Readnour Director
    Planned sale
    $213K 35,402 shares at $6.01 5.3% of stake
    Traded Aug 17 Filed Aug 19
    ↗

Also filed in the last 12 months, not counted as buying or selling: 18 stock grants, 14 sales to cover taxes, and 1 gift.

SEC filings

Recent issuer filings from EDGAR, 12 shown.

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.07 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
424B5 Filing Doc
424B3 Filing Doc
8-K 8.01,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.